IPOs

Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall
Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall
Endpoints
Rhythm Pharmaceuticals
IPOs
obesity
rare disease
Flag link:
ASCO spotlight presaged two more biotech IPOs angling for $215M
ASCO spotlight presaged two more biotech IPOs angling for $215M
Endpoints
ASCO
IPOs
biotech
Deciphera
DCC-2618
Nucana
Acelarin
Flag link:
Peregrine slashes R&D in a reorg that claims 60 jobs; Zai Labs in hunt for $150M IPO – report
Peregrine slashes R&D in a reorg that claims 60 jobs; Zai Labs in hunt for $150M IPO – report
Endpoints
Peregrine Pharmaceuticals
reorganization
Zai Labs
IPOs
Flag link:
Eyeing an IPO, Sutro retools its $1B I/O deal with Celgene but stays focused on BCMA
Eyeing an IPO, Sutro retools its $1B I/O deal with Celgene but stays focused on BCMA
Endpoints
IPOs
Sutro
Celgene
BCMA
Flag link:
Kala Pharmaceuticals prices $90m IPO
Kala Pharmaceuticals prices $90m IPO
Drug Delivery Business News
Kala Pharmaceuticals
IPOs
cataract surgery
Flag link:
Ionis-spinout Akcea prices IPO below expected range
Ionis-spinout Akcea prices IPO below expected range
Drug Delivery Business News
Akcea
Ionis
IPOs
Volanesorsen
Flag link:
Biotech IPOs more than double in Q2
Biotech IPOs more than double in Q2
BioPharma Dive
biotech
IPOs
BeyondSprings Therapeutics
Jounce Therapeutics
AnaptysBio
Flag link:
Another biotech IPO boasting a pharma castoff rings the bell on Wall Street with $75M haul
Another biotech IPO boasting a pharma castoff rings the bell on Wall Street with $75M haul
Endpoints
IPOs
biotech
Dova Pharmaceuticals
Mersana
Aileron
Flag link:
Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch
Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch
Endpoints
Akcea
biotech
IPOs
Novartis
Flag link:
7 Things You Didn't Know About Gilead Sciences, Inc.
7 Things You Didn't Know About Gilead Sciences, Inc.
Motley Fool
Gilead Sciences
GSK
cash flow
IPOs
Warren Buffett
Flag link:
Argenx IPO haul tops out at $115M, 50% above initial goal
Argenx IPO haul tops out at $115M, 50% above initial goal
Fierce Biotech
Argenx
IPOs
Flag link:
G1 Therapeutics joins a growing biotech winners circle with $105M IPO
G1 Therapeutics joins a growing biotech winners circle with $105M IPO
Endpoints
G1 Therapeutics
IPOs
Flag link:
IPO Preview: Biohaven Pharmaceuticals
IPO Preview: Biohaven Pharmaceuticals
Seeking Alpha
IPOs
Biohaven Pharmaceuticals
Flag link:
Hey Pfizer, Novartis and Eli Lilly. G1 Therapeutics says it can beat all of you in its $115M IPO
Hey Pfizer, Novartis and Eli Lilly. G1 Therapeutics says it can beat all of you in its $115M IPO
Endpoints
G1 Therapeutics
IPOs
Pfizer
Novartis
Eli Lilly
cancer
R&D
Flag link:
Biopharma IPOs sluggish in Q1. Will that continue?
Biopharma IPOs sluggish in Q1. Will that continue?
BioPharma Dive
IPOs
AnaptysBio
Jounce Therapeutics
ObsEva
Valeritas
Flag link:
Candid Truths From A Biotech IPO
Candid Truths From A Biotech IPO
Endpoints
biotech
IPOs
AnaptysBio
Flag link:
Tandem Diabetes Care prices $22.5m public offering
Tandem Diabetes Care prices $22.5m public offering
Drug Delivery Business News
IPOs
Tandem Diabetes
insulin pumps
diabetes
devices
Flag link:
Valeritas raises IPO stakes, looks for $60m
Valeritas raises IPO stakes, looks for $60m
Mass Device
Valeritas
IPOs
insulin delivery
devices
Flag link:
Biotech IPOs off to better start in 2017
Biotech IPOs off to better start in 2017
BioPharma Dive
biotech
IPOs
ObsEva
AnaptysBio
Jounce Therapeutics
Flag link:
An early arrival among ’17 biotech IPOs, AnaptysBio keeps to its range in successful $75M play
An early arrival among ’17 biotech IPOs, AnaptysBio keeps to its range in successful $75M play
Endpoints
AnaptysBio
IPOs
Flag link: